Stocks Overview

LAST PRICE
52.5100
TODAY'S CHANGE (%)
Trending Up2.6000 (5.2094%)

Bid / Lots
50.0100/ 3
Ask / Lots
53.0000/ 36
Open / Previous Close
49.6900 / 49.9100
Day Range
Low 49.6800
High 53.0000
52 Week Range
Low 7.6000
High 59.2300
Volume
467,677
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 49.91
Time	Volume	HROW
09:32 ET	7535	49.69
09:33 ET	1158	49.815
09:37 ET	410	49.92
09:39 ET	2039	49.9
09:42 ET	4011	50.07
09:44 ET	1776	50.01
09:46 ET	2722	50.4999
09:48 ET	2400	50.98
09:50 ET	1732	50.72
09:51 ET	863	50.85
09:53 ET	800	50.65
09:55 ET	200	50.5537
09:57 ET	2771	50.47
10:00 ET	1450	50.31
10:02 ET	700	50.67
10:06 ET	1200	50.58
10:08 ET	718	50.6987
10:09 ET	900	50.4
10:11 ET	100	50.515
10:13 ET	2600	50.4599
10:15 ET	500	50.345
10:18 ET	844	50.4087
10:20 ET	990	50.55
10:22 ET	1190	50.45
10:24 ET	200	50.33
10:26 ET	300	50.31
10:27 ET	500	50.07
10:29 ET	717	50.315
10:31 ET	400	50.1
10:33 ET	1315	50.21
10:36 ET	950	50.38
10:38 ET	1100	50.345
10:40 ET	860	50.215
10:44 ET	1332	50.42
10:47 ET	10961	50.175
10:49 ET	699	49.89
10:51 ET	100	49.82
10:54 ET	1300	50.105
10:56 ET	716	50.0501
11:00 ET	1776	50.65
11:02 ET	3432	50.65
11:03 ET	520	50.6
11:05 ET	1300	50.54
11:07 ET	100	50.555
11:09 ET	300	50.555
11:12 ET	350	50.555
11:14 ET	2453	50.56
11:16 ET	100	50.56
11:18 ET	1833	50.4292
11:20 ET	635	50.59
11:21 ET	100	50.62
11:23 ET	999	50.705
11:27 ET	200	50.6
11:30 ET	681	50.74
11:32 ET	800	50.6869
11:34 ET	454	50.52
11:36 ET	400	50.625
11:38 ET	1200	50.47
11:39 ET	700	50.36
11:41 ET	144	50.46
11:43 ET	200	50.36
11:48 ET	400	50.3999
11:50 ET	400	50.32
11:52 ET	100	50.3576
11:54 ET	100	50.45
11:57 ET	596	50.61
11:59 ET	200	50.6711
12:01 ET	100	50.63
12:03 ET	200	50.57
12:06 ET	200	50.61
12:08 ET	100	50.54
12:12 ET	250	50.54
12:14 ET	410	50.4
12:15 ET	300	50.4
12:17 ET	500	50.4747
12:19 ET	1473	50.51
12:21 ET	800	50.6993
12:24 ET	300	50.77
12:26 ET	730	50.77
12:28 ET	307	50.83
12:30 ET	151	50.8066
12:32 ET	300	50.73
12:35 ET	600	50.82
12:37 ET	300	50.875
12:39 ET	100	50.93
12:44 ET	992	50.81
12:50 ET	100	50.855
12:51 ET	1200	51.185
12:53 ET	2200	51.21
12:55 ET	2000	51.19
12:57 ET	100	51.185
01:00 ET	2271	51.1
01:04 ET	455	51
01:08 ET	1539	51.045
01:09 ET	873	51.06
01:11 ET	600	50.97
01:13 ET	200	51.065
01:15 ET	200	51.0167
01:18 ET	675	50.96
01:22 ET	1300	51.05
01:24 ET	360	51.06
01:26 ET	300	51.09
01:27 ET	896	51.19
01:29 ET	1467	51.31
01:31 ET	500	51.41
01:33 ET	100	51.435
01:36 ET	825	51.5
01:38 ET	1900	51.615
01:40 ET	497	51.635
01:42 ET	1100	51.71
01:44 ET	2143	51.82
01:45 ET	1204	51.72
01:47 ET	1366	51.95
01:49 ET	6233	51.7
01:54 ET	997	51.72
01:56 ET	400	51.75
01:58 ET	500	51.7582
02:00 ET	1592	51.745
02:02 ET	1728	51.72
02:03 ET	1607	51.695
02:05 ET	1110	51.71
02:07 ET	2590	51.527158
02:09 ET	1180	51.51
02:12 ET	3760	51.68
02:14 ET	1147	51.75
02:16 ET	1011	51.75
02:18 ET	1535	51.79
02:20 ET	500	51.77
02:21 ET	3530	52
02:23 ET	400	51.94
02:25 ET	700	52.02
02:27 ET	200	52.07
02:30 ET	200	52.11
02:32 ET	700	52.165
02:34 ET	400	52.18
02:36 ET	209	52.21
02:38 ET	1063	52.3
02:39 ET	2100	52.09
02:41 ET	392	52.1128
02:43 ET	525	52.155
02:45 ET	602	52.29
02:48 ET	200	52.22
02:50 ET	2700	52.18
02:52 ET	400	52.215
02:54 ET	2645	52.23
02:56 ET	300	52.105
02:57 ET	790	52.14
02:59 ET	300	52.21
03:01 ET	300	52.18
03:06 ET	300	52.14
03:08 ET	693	52.227
03:10 ET	500	52.22
03:12 ET	1200	52.25
03:14 ET	2084	52.225
03:15 ET	300	52.295
03:17 ET	200	52.28
03:19 ET	1040	52.28
03:21 ET	617	52.29
03:24 ET	1345	52.295
03:26 ET	301	52.31
03:28 ET	3580	52.39
03:30 ET	300	52.321321
03:32 ET	1512	52.35
03:33 ET	400	52.41
03:35 ET	6605	52.38
03:37 ET	300	52.43
03:39 ET	1701	52.46
03:42 ET	900	52.6
03:44 ET	928	52.65
03:46 ET	18375	52.51
03:48 ET	1125	52.5348
03:50 ET	2441	52.47
03:51 ET	2114	52.545
03:53 ET	3101	52.5
03:55 ET	11595	52.48
03:57 ET	8006	52.435
04:00 ET	48741	52.51

Data delayed at least 15 minutes.

Nov 7, 2024
- Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
- Press Release: Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024, from 7:03AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:03AM ET on Thursday Oct 31, 2024 by Dow Jones
- Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 10, 2024
- Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery, from 7:00AM ET on Thursday Oct 10, 2024 by Dow Jones
  7:00AM ET on Thursday Oct 10, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesHROW Harrow Inc	1.8B	-55.2x	---
United StatesOCUL Ocular Therapeutix Inc	1.7B	-10.2x	---
United StatesLGND Ligand Pharmaceuticals Inc	2.4B	54.5x	-12.71%
United StatesIMCR Immunocore Holdings PLC	1.7B	-32.4x	---
United StatesAVDL Avadel Pharmaceuticals PLC	1.5B	-13.6x	---
United StatesPHAT Phathom Pharmaceuticals Inc	1.2B	-3.3x	---
As of 2024-11-09

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Contact Information

Headquarters: 102 WOODMONT BLVD, SUITE 610NASHVILLE, TN, United States 37215
Phone: 615-733-4731
Fax: 858-345-1745

Executives

Chairman of the Board, Chief Executive Officer: Mark Baum
Chief Financial Officer, Corporate Secretary: Andrew Boll
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer: John Saharek
Lead Independent Director: Perry Sternberg
Independent Director: Adrienne Graves

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$1.8B
Revenue (TTM)	$154.1M
Shares Outstanding	35.5M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.74
EPS	$-0.95
Book Value	$2.01
P/E Ratio	-55.2x
Price/Sales (TTM)	11.5
Price/Cash Flow (TTM)	---
Operating Margin	-5.53%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Harrow Inc
NASDAQ:HROWUnited States

Search Criteria

Charts

Recent News

Nov 7, 2024

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones

Oct 31, 2024

Press Release: Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024, from 7:03AM ET on Thursday Oct 31, 2024 by Dow Jones

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 10, 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery, from 7:00AM ET on Thursday Oct 10, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar